Multiplex Assay Kit for S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay)
MRP8; MIF; 60B8AG; CAGA; CFAG; CGLA; CP-10; L1Ag; NIF; P8; Calgranulin A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 380.00 US$ 394.00 US$ 416.00 US$ 445.00 US$ 475.00 US$ 518.00 US$ 584.00 US$ 730.00
- Quantity
Overview
Properties
- Product No.LMB792Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryTumor immunityInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 80-103 | 87 |
EDTA plasma(n=5) | 97-105 | 101 |
heparin plasma(n=5) | 99-105 | 102 |
sodium citrate plasma(n=5) | 96-105 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of S100 Calcium Binding Protein A8 (S100A8) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 97-104% | 83-92% | 86-95% | 82-93% |
EDTA plasma(n=5) | 88-96% | 78-105% | 79-97% | 87-101% |
heparin plasma(n=5) | 98-105% | 81-93% | 89-98% | 86-99% |
sodium citrate plasma(n=5) | 93-105% | 88-95% | 84-93% | 80-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:S100A8) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese miceScienceDirect: S0006291X1200352X
- Association of Increased S100A8 Serum Protein with Early Pregnancy LossPubmed:25252120
- Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferationPubMed: 25934702
- S100A8 Production in CXCR2-Expressing CD11b+ Gr-1high Cells Aggravates Hepatitis in Mice Fed a High-Fat and High-Cholesterol DietPubMed: 26608915
- Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical ImplementationPubmed:26889680
- Proteomics Analysis of Blood Serums from Alzheimer's Disease Patients Using iTRAQ LabelingTechnology.pubmed:27911324
- Standardized ethanolic extract of the rhizome of Curcuma xanthorrhiza prevents murine ulcerative colitis by regulation of inflammationS1756464617300208
- Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cellspubmed:28498464
- Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds.pubmed:28672877
- Tu1938-Micronutrients Assessment in Patients with Cirrhosis10.1016:S0016-5085(18)33544-3
- Tu1942-PI3K/AKT-Mediated Upregulation of C7 Inhibits Colorectal Cancer Proliferation and Metastasis10.1016:S0016-5085(18)33544-5
- Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammationPubmed:29496993
- S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα.Pubmed:29949169
- Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound modelPubmed: 31116394
- Systemic Inflammation Precedes Microalbuminuria in Diabetes
- iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemiaPubmed: 31440093
- Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective studyPubmed: 31856598
- Analysis of novel serum markers of fibrosis and angiogenesis in patients with alcoholic liver cirrhosis
- Quantification of a panel for dry-eye protein biomarkers in tears: A comparative pilot study using standard ELISA and customized microarrays34012227
- Adjunctive S100A8/A9 Immunomodulation Hinders Cipro fl oxacin Resistance in